Beyond Weight Loss: Could GLP-1 Medications Change the Future of Addiction Treatment?
GLP-1 medications such as tirzepatide (Zepbound®/Mounjaro®) and semaglutide (Wegovy®/Ozempic®) have transformed the treatment of obesity and type 2 diabetes. While most people recognize these medications for helping patients lose weight, researchers have discovered something unexpected: many patients report that they simply “don’t crave” alcohol, cigarettes, or even other compulsive behaviors the way they once did.
These observations have sparked one of the most exciting areas of research in addiction medicine.
The Brain Connection
GLP-1 is a naturally occurring hormone best known for regulating blood sugar and appetite. However, GLP-1 receptors are also found throughout the brain—particularly within the mesolimbic reward system, the network responsible for motivation, pleasure, and reinforcement.
When activated, GLP-1 receptors appear to reduce dopamine release triggered by addictive substances. Rather than creating a “high,” these medications may make alcohol, nicotine, and other rewarding behaviors feel less reinforcing, leading many people to experience fewer cravings and improved control over compulsive behaviors. (PubMed Central (PMC) (https://pmc.ncbi.nlm.nih.gov/articles/PMC13181353/?utm_source=chatgpt.com))
Alcohol Use Disorder: The Strongest Evidence So Far
Among all addictions studied, alcohol use disorder currently has the best clinical evidence.
In the first randomized controlled trial of semaglutide for alcohol use disorder, researchers assigned 48 adults to receive either weekly semaglutide or placebo for nine weeks. Participants receiving semaglutide:
Consumed significantly less alcohol during laboratory drinking sessions.
Experienced lower weekly alcohol cravings.
Reduced the number of drinks consumed on drinking days.
Demonstrated greater reductions in heavy-drinking episodes than those receiving placebo.
While not every drinking outcome improved, the results were encouraging enough that investigators concluded larger clinical trials are warranted. (PubMed Central (PMC) (https://pmc.ncbi.nlm.nih.gov/articles/PMC11822619/?utm_source=chatgpt.com))
More recently, systematic reviews combining randomized trials, observational studies, and neuroimaging research have reached similar conclusions. Semaglutide and liraglutide consistently demonstrate reductions in alcohol consumption, relapse rates, and alcohol-related medical events, although researchers emphasize that larger trials are still needed before these medications become standard treatment for alcohol use disorder. (ScienceDirect (https://www.sciencedirect.com/science/article/pii/S2589537025005796?utm_source=chatgpt.com))
What About Nicotine?
The story is more mixed.
Animal studies consistently demonstrate reduced nicotine intake when GLP-1 receptors are activated. Human studies have shown promising reductions in cravings and cigarette consumption in some individuals, but randomized trials have not yet shown higher long-term smoking cessation rates compared with standard treatment alone.
At this time, GLP-1 medications should not replace established smoking-cessation therapies such as counseling, nicotine replacement, or varenicline. (PubMed Central (PMC) (https://pmc.ncbi.nlm.nih.gov/articles/PMC13181353/?utm_source=chatgpt.com))
Could GLP-1 Medications Help Other Addictions?
Researchers are also investigating whether GLP-1 medications may benefit patients with:
Opioid use disorder
Cocaine or stimulant addiction
Cannabis use disorder
Binge eating disorder
Food addiction
Gambling disorder
Other compulsive behaviors
Animal studies have consistently shown reductions in drug-seeking behavior across multiple substances. Human observational studies involving hundreds of thousands of patients have reported lower rates of alcohol misuse, opioid overdose, nicotine dependence, cocaine use disorder, and addiction-related hospitalizations among individuals prescribed GLP-1 medications. However, these studies demonstrate associations—not proof of cause and effect. Randomized clinical trials are still required before these medications can be recommended specifically for treating these conditions. (AP News (https://apnews.com/article/c74683839a5196cc679d8008ba619451?utm_source=chatgpt.com))
Why Are Researchers So Excited?
For decades, addiction treatment has relied on relatively few FDA-approved medications. Although these therapies are highly effective for many patients, relapse rates remain substantial, and additional treatment options are desperately needed.
GLP-1 medications may represent an entirely new therapeutic pathway because they appear to act on the brain’s reward circuitry rather than simply blocking a specific drug or replacing it. This creates the possibility that one medication could eventually help multiple addictive disorders by reducing cravings at their neurologic source. (Springer Link (https://link.springer.com/article/10.1007/s11606-025-09498-3?utm_source=chatgpt.com))
What We Still Don’t Know
Although the research is exciting, important questions remain:
Which GLP-1 medication works best?
Is tirzepatide more effective than semaglutide?
What is the optimal dose for addiction treatment?
Do benefits continue after stopping the medication?
Which patients benefit the most?
Can these medications improve long-term recovery when combined with counseling?
Large multicenter clinical trials are currently underway to answer these questions. (Wiley Online Library (https://onlinelibrary.wiley.com/doi/full/10.1111/bcpt.70004?utm_source=chatgpt.com))
The Bottom Line
GLP-1 medications are changing far more than body weight.
Growing evidence suggests these medications may influence the brain’s reward system, reducing cravings and compulsive behaviors in ways researchers never anticipated. The strongest human evidence currently supports their potential role in reducing alcohol consumption, while promising data continue to emerge for nicotine, opioids, and other addictive disorders.
Although GLP-1 medications are not currently FDA-approved to treat addiction, the science is advancing rapidly. Over the next several years, these medications may become an important addition to the treatment options available for substance use disorders and compulsive behaviors.
As always, these medications should only be used under the supervision of a qualified healthcare professional and should complement—not replace—evidence-based addiction treatment when needed.
⸻
References
Klein KR, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025. (PubMed Central (PMC) (https://pmc.ncbi.nlm.nih.gov/articles/PMC11822619/?utm_source=chatgpt.com))
Patil A, et al. Effects of GLP-1 Receptor Agonists on Alcohol Consumption: A Systematic Review and Meta-analysis. 2025. (ScienceDirect (https://www.sciencedirect.com/science/article/pii/S2589537025005796?utm_source=chatgpt.com))
Woo MA, et al. GLP-1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review. Alcohol Clin Exp Res. 2026. (PubMed Central (PMC) (https://pmc.ncbi.nlm.nih.gov/articles/PMC13181353/?utm_source=chatgpt.com))
Lira MC, Barrett E, Coffey MJ. GLP-1 Receptor Agonists: Encouraging Signals for Treating Alcohol Use Disorder. Journal of General Internal Medicine. 2025. (Springer Link (https://link.springer.com/article/10.1007/s11606-025-09498-3?utm_source=chatgpt.com))
